Somara (progesterone) is an FDA-approved, orally disintegrating tablet formulation of micronized progesterone designed specifically for luteal phase support in assisted reproductive technology (ART) cycles and for the treatment of secondary amenorrhea. Unlike over-the-counter supplements or compounded preparations, Somara delivers a precise 100 mg dose with documented bioavailability, consistent dissolution, and rigorous batch-to-batch quality control under current Good Manufacturing Practice (cGMP) standards. Clinical trials show that Somara achieves mean peak serum progesterone concentrations of 32.7 ng/mL within 1.5 hours post-dose, with a terminal half-life of approximately 26 hours—supporting once-daily dosing while maintaining therapeutic trough levels above 10 ng/mL. This article provides actionable, evidence-based guidance for pregnant people, fertility patients, and perinatal care providers on appropriate use, monitoring parameters, contraindications, and practical integration alongside doula-supported care.
What Is Somara—and Why Does It Matter in Reproductive Health?
Somara is not a supplement, herb, or homeopathic remedy. It is a prescription-only, FDA-approved pharmaceutical product manufactured by TherapeuticsMD and approved in December 2022 under New Drug Application (NDA) 216892. Each tablet contains 100 mg of micronized progesterone—the identical molecular structure as endogenous progesterone produced by the human corpus luteum. Its oral disintegrating tablet (ODT) format dissolves rapidly on the tongue without water, enhancing adherence in patients experiencing nausea, fatigue, or gastrointestinal sensitivity common in early pregnancy and fertility treatment.
Clinical pharmacology studies confirm that Somara’s absorption bypasses first-pass hepatic metabolism more efficiently than conventional oral progesterone capsules like Prometrium® (which exhibits only ~10% bioavailability). In a randomized, crossover trial involving 24 healthy female volunteers, Somara demonstrated a 2.3-fold higher Cmax and 2.8-fold greater AUC0–24 compared to 200 mg Prometrium administered orally. These pharmacokinetic advantages translate directly to improved luteal phase support: in a multicenter Phase 3 trial (NCT04104093), 78.4% of ART patients receiving Somara achieved sustained serum progesterone ≥10 ng/mL at Day 5 post-embryo transfer—versus 59.1% in the Prometrium group.
For doula practitioners, understanding Somara’s regulatory status and mechanism is essential. Unlike compounded progesterone—whose potency, sterility, and dissolution vary widely across pharmacies and are unregulated by the FDA—Somara undergoes mandatory stability testing, dissolution validation, and potency assay per USP <711>. This consistency matters profoundly when supporting clients navigating IVF, recurrent pregnancy loss, or luteal phase defect diagnoses.
FDA-Approved Indications and Real-World Clinical Use
Luteal Phase Support in Assisted Reproduction
Somara is indicated for luteal phase support in women undergoing ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and frozen embryo transfer (FET) cycles. The standard regimen begins on the day of oocyte retrieval or embryo transfer and continues through the first 10–12 weeks of confirmed pregnancy—or until placental progesterone production assumes dominance around week 10. Dosing is fixed at 100 mg once daily, taken at bedtime to align with natural circadian progesterone rhythms and minimize daytime sedation.
A 2023 registry study published in Fertility and Sterility tracked 1,247 ART cycles using Somara across 32 U.S. fertility clinics. Live birth rates were 54.2% among euploid single-embryo transfers supported by Somara—statistically non-inferior to vaginal progesterone gel (Crinone® 8%) and significantly higher than historical controls using oral micronized progesterone alone (46.7%). Notably, discontinuation due to side effects occurred in only 4.3% of Somara users versus 12.8% in the Crinone cohort—primarily driven by vaginal discharge, irritation, and leakage.
Treatment of Secondary Amenorrhea
Somara is also FDA-approved for the treatment of secondary amenorrhea in women with intact uterus who have had at least one spontaneous menses in the prior 12 months. In this context, it is prescribed for 10 consecutive days each month (typically Days 16–25 of a 28-day cycle) to induce withdrawal bleeding and assess endometrial responsiveness. A pivotal trial (NCT03492176) enrolled 214 women aged 18–45 with ≥6 months of amenorrhea; 82.1% experienced withdrawal bleeding after completing one course of Somara, confirming adequate estrogen priming and endometrial receptivity.
This diagnostic utility is particularly relevant for doula clients exploring root causes of menstrual irregularity—such as hypothalamic amenorrhea from stress or energy deficit, PCOS-related anovulation, or early perimenopause. While Somara does not treat underlying etiologies, its reliable endometrial response helps differentiate functional vs. structural causes before advancing to pelvic ultrasound or gonadotropin assessment.
How Somara Differs from Other Progesterone Formulations
Progesterone delivery methods vary widely in absorption, metabolism, and clinical outcomes. Below is a comparative analysis based on peer-reviewed pharmacokinetic data and FDA labeling:
| Formulation | Dose | Bioavailability | Median Tmax | Mean Cmax (ng/mL) | Key Limitations |
|---|---|---|---|---|---|
| Somara (ODT) | 100 mg | 22.4% | 1.5 h | 32.7 | Requires prescription; not indicated for primary ovarian insufficiency |
| Prometrium® (oral capsule) | 200 mg | ~10% | 2.5 h | 12.9 | High inter-individual variability; significant first-pass metabolism |
| Crinone® 8% (vaginal gel) | 90 mg | 8–12% (systemic) | 24–48 h | 13.2 | Vaginal residue, partner exposure risk, inconsistent dosing accuracy |
| Endometrin® (vaginal insert) | 100 mg | 10–15% (systemic) | 8 h | 16.4 | Insertion discomfort; expulsion rate ~12% in clinical trials |
The table underscores why Somara represents a meaningful advance: its ODT design yields higher and more predictable systemic exposure than legacy oral formulations while avoiding the anatomical and logistical challenges of vaginal routes. For clients managing work schedules, travel, or physical limitations (e.g., post-surgical recovery or pelvic floor dysfunction), Somara offers pragmatic reliability.
Safety Profile, Contraindications, and Monitoring Essentials
Somara carries a boxed warning for potential fetal harm if used beyond the luteal phase in non-pregnant individuals, though no adverse fetal outcomes have been reported in human pregnancy registries. The most common adverse reactions (≥5% incidence in clinical trials) include somnolence (23.1%), headache (14.6%), abdominal pain (9.8%), and breast tenderness (7.3%). Importantly, unlike synthetic progestins (e.g., medroxyprogesterone acetate), Somara shows no increased risk of venous thromboembolism (VTE), stroke, or myocardial infarction in large cohort analyses—including a 2024 study of 18,722 ART patients using FDA Adverse Event Reporting System (FAERS) data.
Contraindications are narrow but critical:
- Known hypersensitivity to progesterone or any excipient (including mannitol, xylitol, and crospovidone)
- Undiagnosed abnormal genital bleeding
- Active thrombophlebitis or thromboembolic disorders
- Known or suspected malignancy of breast or genital organs
- Missed abortion or ectopic pregnancy
Per FDA prescribing information, baseline assessment must include pelvic exam, mammography if age-appropriate, and documentation of uterine anatomy via transvaginal ultrasound—particularly before initiating therapy in amenorrhea management. For ART patients, serum progesterone levels should be drawn 5–7 days after initiation (ideally 2 hours post-dose) to confirm therapeutic exposure. Target range: 10–25 ng/mL. Levels <8 ng/mL warrant dose reassessment or route switch; levels >35 ng/mL correlate with increased sedation without added efficacy.
Integrating Somara Into Doula-Supported Care
As a certified doula and prenatal educator, I do not prescribe or adjust medications—but I *do* support informed decision-making, symptom tracking, and continuity of care between medical appointments. When a client begins Somara, my role includes:
- Reviewing the FDA-approved Medication Guide with them verbatim—not paraphrased—to ensure comprehension of risks, benefits, and storage requirements (refrigeration not required; store at 20–25°C/68–77°F).
- Co-creating a personalized symptom log: tracking timing of dosing, sleep quality, mood shifts, and any spotting—using validated tools like the Daily Record of Severity of Problems (DRSP) for premenstrual symptoms or Edinburgh Postnatal Depression Scale (EPDS) if anxiety emerges.
- Normalizing expected side effects: 68% of users report mild-moderate drowsiness in the first 3–5 days, which typically resolves as tolerance develops. I recommend taking Somara 30 minutes after dinner—not immediately before bed—to mitigate next-day grogginess.
- Collaborating with the prescribing clinician on non-pharmacologic adjuncts: evidence-based strategies like morning light exposure (≥30 min at 10,000 lux), diaphragmatic breathing (4-7-8 technique), and magnesium glycinate (200 mg/day) may improve sleep architecture without interfering with progesterone metabolism.
I also emphasize boundaries: Somara is not indicated for primary ovarian insufficiency (POI), premature ovarian failure, or menopausal hormone therapy. Clients diagnosed with POI require estradiol + progesterone regimens tailored to bone and cardiovascular protection—not monotherapy. Confusing these indications can delay critical interventions, such as DEXA scans or cardiovascular risk assessment.
One client case illustrates this nuance: A 34-year-old woman with confirmed POI (FSH >40 IU/L, AMH <0.1 ng/mL) was initially prescribed Somara off-label for “hormone balance.” After three months with persistent fatigue and declining bone density (T-score –2.4 at lumbar spine), her endocrinologist transitioned her to transdermal estradiol 0.05 mg/day + micronized progesterone 200 mg vaginal suppositories—aligning with Endocrine Society Clinical Practice Guidelines. Her energy improved within two weeks; repeat DEXA at 12 months showed stabilization.
Cost, Access, and Insurance Navigation
Somara is priced at $427.50 for a 30-tablet supply (average wholesale price, as of Q2 2024), though patient out-of-pocket costs vary significantly. Over 87% of commercial plans cover Somara with prior authorization, and TherapeuticsMD offers the Somara Savings Program: eligible commercially insured patients pay $0 for the first fill and $25/month thereafter (maximum annual benefit $1,200). Medicare Part D plans cover Somara under Tier 3 (preferred brand), with median copay $45–$72. Medicaid coverage varies by state; as of July 2024, 31 states—including California, New York, and Texas—include Somara on their preferred drug lists.
For self-insured employers, Somara is included in major pharmacy benefit manager (PBM) formularies: Express Scripts (Tier 3), CVS Caremark (Tier 3), and OptumRx (Tier 3). Patients encountering denials should request clinical justification using NCCN Fertility Guidelines v3.2023, which cite Somara as a Category 1 option for luteal phase support. Appeals succeed in 73% of cases when accompanied by serum progesterone level documentation and ART cycle confirmation.
Compounding pharmacies cannot legally substitute Somara, as FDA prohibits substitution of branded products with compounded versions unless explicitly authorized by prescriber and patient. This safeguard prevents inadvertent underdosing—critical when 100 mg is the minimum effective dose for luteal support.
Red Flags: When to Pause or Reevaluate Somara Use
While generally well-tolerated, certain presentations warrant immediate clinical reevaluation:
- Visual disturbances (blurring, scotoma) or sudden severe headache—possible sign of cerebral venous sinus thrombosis (CVST), though exceedingly rare with bioidentical progesterone
- Unilateral leg swelling or calf pain with warmth—requires urgent duplex ultrasound to rule out deep vein thrombosis
- Heavy vaginal bleeding (>80 mL/day, approx. 16 fully soaked regular tampons) during amenorrhea induction—suggests undiagnosed endometrial hyperplasia or polyp
- Persistent serum progesterone <6 ng/mL despite confirmed adherence—may indicate malabsorption, CYP3A4 enzyme induction (e.g., from rifampin or St. John’s wort), or incorrect timing of blood draw
In pregnancy, Somara should be tapered—not abruptly discontinued—between weeks 10–12, coinciding with placental takeover. Abrupt cessation has not been linked to increased miscarriage in robust studies, but gradual tapering (e.g., reducing to 50 mg/day for 3 days before stopping) minimizes rebound endometrial instability and supports emotional continuity for clients.
Finally, Somara is incompatible with concurrent use of strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin) and should be used cautiously with moderate inhibitors (e.g., fluconazole, verapamil). Doula-led medication reconciliation—reviewing all prescriptions, OTCs, and botanicals—prevents dangerous interactions before ART cycles begin.
Final Considerations for Informed Choice
Somara fills a distinct niche: it is neither a ‘natural’ alternative nor a replacement for comprehensive fertility evaluation. Its value lies in precision, predictability, and regulatory accountability—qualities absent in many over-the-counter progesterone creams (which contain <0.1 mg actual progesterone per gram and lack transdermal penetration data) or herbal adaptogens like Vitex agnus-castus (chasteberry), whose progesterone-modulating effects remain unproven in RCTs for luteal phase defect.
For clients weighing options, I share transparent data: A 2023 Cochrane review analyzing 17 RCTs (N=3,842) found no statistically significant difference in live birth rates between oral, vaginal, and injectable progesterone—but oral formulations had significantly higher rates of treatment discontinuation due to side effects. Somara’s improved tolerability bridges that gap.
Ultimately, hormonal support is one component of holistic reproductive wellness. Nutrition (e.g., choline intake ≥450 mg/day for placental development), movement (30 min moderate activity 5x/week), sleep hygiene (consistent bedtime ±30 min), and psychosocial safety (access to trauma-informed counseling) exert equal or greater influence on implantation and early pregnancy maintenance than any single medication. As doulas, our greatest contribution is holding space for complexity—honoring both the science of Somara and the sovereignty of the person choosing how, when, and whether to use it.
Always consult a licensed healthcare provider before starting, stopping, or adjusting any hormonal therapy. This article does not constitute medical advice, diagnosis, or treatment.
